BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38050808)

  • 1. Characterization of colorectal cancer by hierarchical clustering analyses of five immune cell markers.
    Ito S; Koshino A; Komura M; Kato S; Otani T; Wang C; Ueki A; Takahashi H; Ebi M; Ogasawara N; Tsuzuki T; Kasai K; Kasugai K; Takiguchi S; Takahashi S; Inaguma S
    Pathol Int; 2024 Jan; 74(1):13-25. PubMed ID: 38050808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
    Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
    Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of Pleural Mesothelioma by Hierarchical Clustering Analyses Using Immune Cells within Tumor Microenvironment.
    Inaguma S; Wang C; Ito S; Ueki A; Lasota J; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Takiguchi S; Schrump DS; Miettinen M; Takahashi S
    Pathobiology; 2024 Mar; ():1-13. PubMed ID: 38527431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and Prognostic Significance of CD47-SIRPA Macrophage Checkpoint Molecules in Colorectal Cancer.
    Sugimura-Nagata A; Koshino A; Inoue S; Matsuo-Nagano A; Komura M; Riku M; Ito H; Inoko A; Murakami H; Ebi M; Ogasawara N; Tsuzuki T; Takahashi S; Kasugai K; Kasai K; Inaguma S
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33799989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined prognostic value of CD274 (PD-L1)/PDCDI (PD-1) expression and immune cell infiltration in colorectal cancer as per mismatch repair status.
    Ahtiainen M; Wirta EV; Kuopio T; Seppälä T; Rantala J; Mecklin JP; Böhm J
    Mod Pathol; 2019 Jun; 32(6):866-883. PubMed ID: 30723299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterisation of tumor microenvironment and prevalence of CD274/PD-L1 genetic alterations difference in colorectal Cancer.
    Yang L; Liu S; He W; Xiong Z; Xia L
    BMC Cancer; 2023 Mar; 23(1):221. PubMed ID: 36894899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma.
    Lee LH; Cavalcanti MS; Segal NH; Hechtman JF; Weiser MR; Smith JJ; Garcia-Aguilar J; Sadot E; Ntiamoah P; Markowitz AJ; Shike M; Stadler ZK; Vakiani E; Klimstra DS; Shia J
    Mod Pathol; 2016 Nov; 29(11):1433-1442. PubMed ID: 27443512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1/PD-1 crosstalk in colorectal cancer: are we targeting the right cells?
    Cantero-Cid R; Casas-Martin J; Hernández-Jiménez E; Cubillos-Zapata C; Varela-Serrano A; Avendaño-Ortiz J; Casarrubios M; Montalbán-Hernández K; Villacañas-Gil I; Guerra-Pastrián L; Peinado B; Marcano C; Aguirre LA; López-Collazo E
    BMC Cancer; 2018 Oct; 18(1):945. PubMed ID: 30285662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RHAMM in liver metastases of stage IV colorectal cancer with mismatch-repair proficient status correlates with tumor budding, cytotoxic T-cells and PD-1/PD-L1.
    Burren S; Reche K; Blank A; Galvàn JA; Dawson H; Berger MD; Zlobec I; Lugli A
    Pathol Res Pract; 2021 Jul; 223():153486. PubMed ID: 34051513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer.
    Möller K; Blessin NC; Höflmayer D; Büscheck F; Luebke AM; Kluth M; Hube-Magg C; Zalewski K; Hinsch A; Neipp M; Mofid H; Lárusson H; Daniels T; Isbert C; Coerper S; Ditterich D; Rupprecht H; Goetz A; Bernreuther C; Sauter G; Uhlig R; Wilczak W; Simon R; Steurer S; Minner S; Burandt E; Krech T; Perez D; Izbicki JR; Clauditz TS; Marx AH
    Acta Oncol; 2021 Sep; 60(9):1210-1217. PubMed ID: 34092167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
    Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
    Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune microenvironment in patients with mismatch-repair-proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study.
    Jary M; Liu WW; Yan D; Bai I; Muranyi A; Colle E; Brocheriou I; Turpin A; Radosevic-Robin N; Bourgoin P; Penault-Llorca F; Cohen R; Vernerey D; André T; Borg C; Shanmugam K; Svrcek M
    Mol Oncol; 2022 Jun; 16(11):2260-2273. PubMed ID: 34954864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presence of Tim3
    Klapholz M; Drage MG; Srivastava A; Anderson AC
    J Pathol; 2022 Jun; 257(2):186-197. PubMed ID: 35119692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapy.
    Wu F; Jiang T; Chen G; Huang Y; Zhou J; Lin L; Feng J; Wang Z; Shu Y; Shi J; Hu Y; Wang Q; Cheng Y; Chen J; Lin X; Wang Y; Huang J; Cui J; Cao L; Liu Y; Zhang Y; Pan Y; Zhao J; Wang L; Chang J; Chen Q; Ren X; Zhang W; Fan Y; He Z; Fang J; Gu K; Dong X; Zhang T; Shi W; Zou J; Bai X; Ren S; Zhou C;
    Cancer Commun (Lond); 2022 Dec; 42(12):1331-1346. PubMed ID: 36331328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma.
    Noh BJ; Kwak JY; Eom DW
    BMC Cancer; 2020 Jan; 20(1):58. PubMed ID: 31992245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and validation of a novel survival prediction model based on the T-cell phenotype in the tumor immune microenvironment and peripheral blood for gastric cancer prognosis.
    Ma J; Li J; He N; Qian M; Lu Y; Wang X; Wu K
    J Transl Med; 2023 Feb; 21(1):73. PubMed ID: 36737759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of programmed cell death-ligand expression in small bowel adenocarcinoma is determined by the tumor microenvironment.
    Hoshimoto A; Tatsuguchi A; Hamakubo R; Nishimoto T; Omori J; Akimoto N; Tanaka S; Fujimori S; Hatori T; Shimizu A; Iwakiri K
    World J Gastroenterol; 2023 Oct; 29(40):5566-5581. PubMed ID: 37970475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer.
    Wu X; Lan X; Hu W; Zhang W; Lai X; Xu S; Li J; Qiu W; Wang W; Xiao J; Wang F; Ding Y; Liang L
    Cancer Immunol Immunother; 2021 Nov; 70(11):3235-3248. PubMed ID: 33818637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Marker Spatial Distribution and Clinical Outcome after PD-1 Blockade in Mismatch Repair-deficient, Advanced Colorectal Carcinomas.
    Saberzadeh-Ardestani B; Graham RP; McMahon S; Ahanonu E; Shi Q; Williams C; Hubbard A; Zhang W; Muranyi A; Yan D; Jin Z; Shanmugam K; Sinicrope FA
    Clin Cancer Res; 2023 Oct; 29(20):4268-4277. PubMed ID: 37566222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.